Speaker Profile
EVP, Kite Pharma
Biography
Cindy Perettie is a global oncology and cell therapy leader with more than two decades of experience advancing medicines from science to patients. She leads Kite’s cell therapy business, building on the company’s foundation in CAR T and its approved therapies for blood cancers. Her career spans strategy, commercialization, global operations, and patient access, with prior senior leadership roles at Roche/Genentech focused on oncology. At Kite, she is driving the next phase of cell therapy, including broader patient reach, manufacturing scale, community-based delivery, and expansion into next-generation platforms. She has also emphasized the personal and human side of cancer care, connecting scientific innovation with the practical realities patients and families face. Her leadership reflects a central challenge for the field: how to turn highly complex, individualized therapies into treatments that can reach more eligible patients safely, reliably, and at global scale.
Talk
Track 1 Chair
To be determined
Session Abstract – PMWC 2027 Silicon Valley
Track Chair:
Cindy Perettie, Kite Pharma
PMWC Award Ceremony
• Katy Rezvani, MD Anderson (Luminary)
• David Miklos, Stanford (Luminary)
• Frederick Locke, Moffitt Cancer Center (Luminary)
Featured Speakers
• Katy Rezvani, MD Anderson
• David Miklos, Stanford
• Frederick Locke, Moffitt Cancer Center
• Arie Belldegrun, Allogene Therapeutics
• Paul Hastings, Nkarta Therapeutics
• Priti Hegde, Kite Pharma
• Andrew Scharenberg, Umoja Biopharma
• Brett Staahl, Scribe Therapeutics
• Marcela Maus, Mass General Brigham / Harvard
• Antoni Ribas, UCLA
• Saul Priceman, USC
• Sabine Heitzeneder, Stanford
Off-the-Shelf Cell Therapies
NK, iPSC, and allogeneic T cells: what wins beyond autologous CAR-T.
AI in Cell Therapy: Research to Commercialization
How AI is reshaping discovery, product design, manufacturing, and clinical translation.
The Bottleneck: Manufacturing at Scale
Capacity, automation, cost of goods, and the realities of getting engineered cells to patients.
In Vivo Delivery: The Make-or-Break Layer
Targeting the right tissue safely enough to make in vivo engineering real.
Why Cell Therapies Fail in Solid Tumors and What Works
The microenvironment, antigen escape, and programs showing real responses.
Approved to Effective
Real-world outcomes, access, and what CAR-T still gets wrong after approval.
PMWC Hall of Impact
Previous Speakers Include
Nobel laureates, technology founders, regulators, CEOs and scientific pioneers who have taken the PMWC stage.
